IRIX (IRIDEX) Moat Score: 4/10 (As of Jun. 26, 2026)


IRIX IRIDEX Corp IRIX
66 GF Score
Price $1.18
GF Value $1.70
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is IRIDEX Moat Score?

IRIDEX IRIX +0.34% 66 Moat Score is 4 as of Jun. 26, 2026. GuruFocus rates IRIX with a GF Score™ of 66/100 and a GF Value™ of $1.70 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 846 Medical Devices & Instruments companies, IRIDEX ranks better than 83.22% on this metric.

IRIDEX has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

IRIDEX has Narrow Moat: IRIDEX Corp has a modest moat due to its specialized laser systems for ophthalmology, which provide some customer loyalty and switching costs. However, it faces competition and lacks significant scale or brand strength to elevate its moat to a stronger level.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes IRIDEX might have Narrow Moat - Discernible but modest moat.

IRIDEX  (NAS:IRIX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

IRIDEX Moat Score Related Terms

IRIX vs ICCM, ADGM, CSDX: Moat Score Comparison

For the Medical Devices subindustry, IRIDEX's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IRIDEX Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, IRIDEX's Moat Score distribution charts can be found below:

* The bar in red indicates where IRIDEX's Moat Score falls into.


IRIX
66GF Score
IRIDEX Corp IRIX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
IRIDEX (IRIX) has a Moat Score of 4 as of Jun. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, IRIDEX ranks #142 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 16.8%.
Is IRIDEX's Moat Score too high?
IRIDEX's current Moat Score is 4. Based on the distribution chart, IRIDEX ranks #142 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, IRIDEX has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IRIDEX's Moat Score compare to ICCM and ADGM?
According to the Medical Devices & Instruments industry distribution chart, IRIDEX ranks #142 out of 846 companies for Moat Score. This places IRIDEX in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. IRIDEX's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IRIDEX stock overvalued right now?
Based on GuruFocus' analysis, IRIDEX (IRIX) is currently considered Possible Value Trap. The stock's GF Value™ is $1.70, compared to a current price of $1.18 — trading 30.4% below its estimated fair value. The current Moat Score is 4. IRIDEX's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For IRIDEX (IRIX), the current Moat Score is 4 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IRIDEX (IRIX) Overvalued in 2026?

Based on GuruFocus' analysis, IRIDEX stock appears to be undervalued. The current stock price of $1.18 is trading 30.4% below its estimated GF Value™ of $1.70. GuruFocus considers IRIDEX to be Possible Value Trap.

Key valuation signals for IRIX:

  • Moat Score: 4
  • GF Value™: $1.70 vs. price of $1.18 (30.4% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the IRIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IRIDEX Business Description

Address 1212 Terra Bella Avenue, Mountain View, CA, USA, 94043
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
66GF Score

Get the complete analysis for IRIX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.18
Price
$1.70
GF Value